High performance liquid chromatographic analysis of MS23 piperidine analog MSP001 in rat plasma

MSP001 is a newly synthesized piperidine analog of the lead antihypertensive compound MS23 that dually targets cAMP-specific type 4 phosphodiesterase and L-type calcium channels. We validated an analytical protocol for MSP001 in rat plasma using high performance liquid chromatographic method. A C18...

Full description

Saved in:
Bibliographic Details
Published in:Journal of pharmaceutical and biomedical analysis 2006-11, Vol.42 (5), p.607-612
Main Authors: Wang, Ting, Wang, Desuo
Format: Article
Language:English
Subjects:
Analysis
Analytical, structural and metabolic biochemistry
Animals
Antihypertensive
Antihypertensive Agents - blood
Biological and medical sciences
Calibration
Chromatography, High Pressure Liquid
Drug Stability
Dual action
Female
Fundamental and applied biological sciences. Psychology
General pharmacology
Injections, Intravenous
Medical sciences
MS23
MSP001
Pharmacology. Drug treatments
Piperidines - blood
Pyrroles - blood
Rats
Rats, Sprague-Dawley
Reference Standards
Reproducibility of Results
Sensitivity and Specificity
Validation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:MSP001 is a newly synthesized piperidine analog of the lead antihypertensive compound MS23 that dually targets cAMP-specific type 4 phosphodiesterase and L-type calcium channels. We validated an analytical protocol for MSP001 in rat plasma using high performance liquid chromatographic method. A C18 column and a phosphate/acetonitrile buffer were used to perform the chromatographic separation. UV detection was carried out at 307 nm, a wavelength at which an absorption peak was detected for this group of compounds. The calibration curve for MSP001 was linear in the range from 25 to 10,000 ng/ml. The limit of quantification (LOQ) was 25 ng/ml. The results demonstrate that this method has high linearity ( R = 0.99995), compound specificity, and acceptable precision/accuracy. The protocol is suitable for in vivo pharmacokinetic studies on the compound.
ISSN:0731-7085
1873-264X
DOI:10.1016/j.jpba.2006.05.010